David A. Siegel Lyra Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 143,900 shares of LYRA stock, worth $40,292. This represents 0.0% of its overall portfolio holdings.

Number of Shares

143,900

Previous 50,700 183.83%

Holding current value

$40,292

Previous $265,000 237.74%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.55 - $6.53 $424,060 - $608,596	93,200 Added 183.83%	143,900 $895,000
Q4 2023 Feb 14, 2024	BUY	$2.82 - $5.24 $142,974 - $265,668	50,700 New	50,700 $265,000
Q1 2023 May 15, 2023	SELL	$1.95 - $3.09 $585 - $927	-300 Reduced 1.05%	28,300 $56,000
Q4 2022 Feb 14, 2023	SELL	$2.44 - $4.92 $34,648 - $69,864	-14,200 Reduced 33.18%	28,600 $89,000
Q3 2022 Nov 14, 2022	BUY	$5.33 - $6.6 $23,452 - $29,040	4,400 Added 11.46%	42,800 $214,000

Q2 2022 Aug 15, 2022	BUY	$4.12 - $7.51 $75,808 - $138,184	18,400 Added 92.0%	38,400 $217,000
Q1 2022 May 16, 2022	SELL	$3.5 - $5.36 $128,450 - $196,712	-36,700 Reduced 64.73%	20,000 $80,000
Q4 2021 Feb 14, 2022	SELL	$4.22 - $9.41 $5,486 - $12,233	-1,300 Reduced 2.24%	56,700 $247,000
Q3 2021 Nov 15, 2021	BUY	$6.06 - $9.43 $84,840 - $132,020	14,000 Added 31.82%	58,000 $529,000
Q2 2021 Aug 16, 2021	BUY	$6.91 - $12.59 $86,831 - $158,205	12,566 Added 39.98%	44,000 $353,000
Q1 2021 May 17, 2021	BUY	$10.38 - $15.61 $326,284 - $490,684	31,434 New	31,434 $364,000

Others Institutions Holding LYRA

# of Institutions

Shares Held

44.4M

Call Options Held

300K

Put Options Held

1.3K

View Full List

About Lyra Therapeutics, Inc.

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $8.91M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

More about LYRA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account